---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002742"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:53:59.399671+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elutia reports preliminary Q4 2025 revenue $3.3M (+16% YoY); eliminates $26.9M debt

## Summary
- Preliminary Q4 net sales ~$3.3M, up 16% YoY, excluding divested BioEnvelope business.
- Repaid full $26.9M debt to SWK Holdings, significantly cutting interest expense.
- Cash on hand $36.3M; $8M escrow from BioEnvelope divestiture expected in 2026.
- Plans FDA filing for NXT-41 base matrix in H1 2026, clearance H2 2026; NXT-41x clearance H1 2027.
- CEO cites $88M EluPro divestiture to Boston Scientific as transformational, funding NXT-41x.

## SEC filing metadata
- accession: 0001104659-26-002742
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465926002742/0001104659-26-002742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465926002742/elut-20260112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002742
- JSON: https://secwatch.observer/filing/0001104659-26-002742.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002742.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.